MX2023013021A - Inhibicion de trampas extracelulares. - Google Patents

Inhibicion de trampas extracelulares.

Info

Publication number
MX2023013021A
MX2023013021A MX2023013021A MX2023013021A MX2023013021A MX 2023013021 A MX2023013021 A MX 2023013021A MX 2023013021 A MX2023013021 A MX 2023013021A MX 2023013021 A MX2023013021 A MX 2023013021A MX 2023013021 A MX2023013021 A MX 2023013021A
Authority
MX
Mexico
Prior art keywords
inhibition
tse
formation
extracellular traps
methods
Prior art date
Application number
MX2023013021A
Other languages
English (en)
Spanish (es)
Inventor
Renato Gerardus Silvano Chirivi
Es Helmuth Hendrikus Gerardus Van
Daphne Montizaan
Eric Charles Meldrum
Original Assignee
Citryll B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP21172160.0A external-priority patent/EP4085973A1/en
Application filed by Citryll B V filed Critical Citryll B V
Publication of MX2023013021A publication Critical patent/MX2023013021A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MX2023013021A 2021-05-04 2022-05-04 Inhibicion de trampas extracelulares. MX2023013021A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21172160.0A EP4085973A1 (en) 2021-05-04 2021-05-04 Inhibition of eosinophil extracellular traps
GB202111541 2021-08-11
PCT/EP2022/061970 WO2022233931A1 (en) 2021-05-04 2022-05-04 Inhibition of eosinophilic traps

Publications (1)

Publication Number Publication Date
MX2023013021A true MX2023013021A (es) 2024-02-12

Family

ID=81392799

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023013021A MX2023013021A (es) 2021-05-04 2022-05-04 Inhibicion de trampas extracelulares.

Country Status (9)

Country Link
US (1) US20250084154A1 (https=)
EP (1) EP4333981A1 (https=)
JP (1) JP2024521638A (https=)
KR (1) KR20240005856A (https=)
AU (1) AU2022270356A1 (https=)
CA (1) CA3215452A1 (https=)
IL (1) IL308223A (https=)
MX (1) MX2023013021A (https=)
WO (1) WO2022233931A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3841120B1 (en) 2018-08-21 2025-09-24 Citryll B.V. Antibodies binding to citrullinated histone 2a and/or 4
EP4442705A1 (en) 2023-04-03 2024-10-09 Citryll B.V. Dosage
GB202318703D0 (en) 2023-12-07 2024-01-24 Citryll B V Diagnostic agent

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ612578A (en) 2005-08-19 2014-11-28 Abbvie Inc Dual variable domain immunoglobin and uses thereof
EP2535349A1 (en) 2007-09-26 2012-12-19 UCB Pharma S.A. Dual specificity antibody fusions
NO2294086T3 (https=) 2008-06-04 2018-02-10
CA2737241C (en) 2008-09-26 2017-08-29 Ucb Pharma S.A. Multivalent antibody fusion proteins
WO2011030107A1 (en) 2009-09-10 2011-03-17 Ucb Pharma S.A. Multivalent antibodies
EP2332987A1 (en) 2009-12-10 2011-06-15 ModiQuest B.V. Anti-inflammatory agents directed against citrullinated epitopes
JP7037940B2 (ja) 2014-12-11 2022-03-17 シトリル べー．フェー． 特発性肺線維症の治療方法
EP3841120B1 (en) 2018-08-21 2025-09-24 Citryll B.V. Antibodies binding to citrullinated histone 2a and/or 4

Also Published As

Publication number Publication date
IL308223A (en) 2024-01-01
KR20240005856A (ko) 2024-01-12
AU2022270356A1 (en) 2023-09-14
JP2024521638A (ja) 2024-06-04
US20250084154A1 (en) 2025-03-13
CA3215452A1 (en) 2022-11-10
WO2022233931A1 (en) 2022-11-10
EP4333981A1 (en) 2024-03-13

Similar Documents

Publication Publication Date Title
MX2023013021A (es) Inhibicion de trampas extracelulares.
CL2020000263A1 (es) Conjugado de anticuerpo monoclonal contra bcma-fármaco.
PE20190115A1 (es) Anticuerpos vista antihumanos y su uso
CL2024002250A1 (es) Uso de anticuerpo anti-vd1 para tratar cáncer, una enfermedad infecciosa o una enfermedad inflamatoria.
MX2019009772A (es) Anticuerpos anti-pd-1 para el tratamiento del cancer de pulmon.
EA202192260A1 (ru) Биомаркеры циклин-зависимой киназы 2 и их применение
CL2019003143A1 (es) Formulaciones estables de anticuerpos anti-ctla4 solos y en combinación con anticuerpos contra el receptor de muerte programada 1 (pd-1) y métodos para su uso.
ECSP10010322A (es) Anticuerpos contra el virus de la influenza y métodos de uso de los mismos
ES2617920T3 (es) Métodos para el tratamiento de la coagulación intravascular diseminada mediante la inhibición de la activación del complemento dependiente de MASP-2
AR110114A1 (es) ANTICUERPOS CONTRA b-AMILOIDE PIROGLUTAMATO Y SUS USOS
PA8794201A1 (es) Anticuerpos anti-cxcr5 humanizados, derivados de los mismos y su uso
BR112019001206A2 (pt) anticorpos monoclonais humanizados que visam ve-ptp (hptp-ss)
CO2020013833A2 (es) Anticuerpo anti-muerte programada-ligando 1 y su uso
PE20231376A1 (es) Anticuerpos contra el sars-cov-2 y metodos e seleccion y uso de los mismos
DOP2006000277A (es) Anticuerpos anti mn y métodos para su utilización
BR112016008409A2 (pt) Uso de um agente inibidor de masp-2 que inibe a ativação de complemento dependente de masp-2
MX2021001902A (es) Anticuerpos que se unen a histona 2a y/o 4 citrulinada.
ECSP21026021A (es) Moduladores de la expresión de pnpla3
MX2019010707A (es) Metodos para tratar y/o prevenir queratosis actinica.
CL2019003485A1 (es) Métodos para redicur la proteinuria en un sujeto humano que padece de nefropatía por inmunoglobulina a. (divisional solicitud 201900909)
MX2020009296A (es) Anticuerpos anti-virus del dengue que tienen reactividad cruzada con el virus zika y metodos de uso.
AR117653A1 (es) Método para tratamiento de miastenia grave
CL2018003167A1 (es) Selección de cepas bacterianas útiles en el tratamiento de alergias.
MX2019007107A (es) Anticuerpo anti-adrenomedulina (adm) o fragmento de anticuerpo anti-adm o supercontigo sin ig anti-adm para su uso en intervencion y terapia de congestion en un paciente con necesidad del mismo.
MX392348B (es) Anticuerpo anti cd43 y uso del mismo para tratamiento del cáncer.